[go: up one dir, main page]

RU2018127882A3 - - Google Patents

Download PDF

Info

Publication number
RU2018127882A3
RU2018127882A3 RU2018127882A RU2018127882A RU2018127882A3 RU 2018127882 A3 RU2018127882 A3 RU 2018127882A3 RU 2018127882 A RU2018127882 A RU 2018127882A RU 2018127882 A RU2018127882 A RU 2018127882A RU 2018127882 A3 RU2018127882 A3 RU 2018127882A3
Authority
RU
Russia
Application number
RU2018127882A
Other versions
RU2747877C2 (ru
RU2018127882A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018127882A publication Critical patent/RU2018127882A/ru
Publication of RU2018127882A3 publication Critical patent/RU2018127882A3/ru
Application granted granted Critical
Publication of RU2747877C2 publication Critical patent/RU2747877C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/485Epidermal growth factor [EGF], i.e. urogastrone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
RU2018127882A 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами RU2747877C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2016070791 2016-01-13
CNPCT/CN2016/070791 2016-01-13
CNPCT/CN2016/076580 2016-03-17
CN2016076580 2016-03-17
EP16195965.5 2016-10-27
EP16195965 2016-10-27
PCT/EP2017/050668 WO2017121850A1 (en) 2016-01-13 2017-01-13 Egf(a) analogues with fatty acid substituents

Publications (3)

Publication Number Publication Date
RU2018127882A RU2018127882A (ru) 2020-02-13
RU2018127882A3 true RU2018127882A3 (ru) 2020-06-19
RU2747877C2 RU2747877C2 (ru) 2021-05-17

Family

ID=57868232

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018127882A RU2747877C2 (ru) 2016-01-13 2017-01-13 Аналоги эфр(а) с заместителями - жирными кислотами

Country Status (26)

Country Link
US (2) US10822385B2 (ru)
EP (1) EP3402811B1 (ru)
JP (2) JP6797926B2 (ru)
KR (1) KR102417487B1 (ru)
CN (1) CN108473550B (ru)
AU (1) AU2017207862B2 (ru)
BR (1) BR112018013820A2 (ru)
CA (1) CA3010756A1 (ru)
CL (1) CL2018001868A1 (ru)
CO (1) CO2018007440A2 (ru)
DK (1) DK3402811T3 (ru)
ES (1) ES2916998T3 (ru)
HR (1) HRP20220720T1 (ru)
HU (1) HUE058647T2 (ru)
IL (1) IL260043A (ru)
LT (1) LT3402811T (ru)
MX (1) MX2018008681A (ru)
MY (1) MY195199A (ru)
PE (1) PE20181376A1 (ru)
PH (1) PH12018501502A1 (ru)
PL (1) PL3402811T3 (ru)
RS (1) RS63298B1 (ru)
RU (1) RU2747877C2 (ru)
SA (1) SA518391996B1 (ru)
SI (1) SI3402811T1 (ru)
WO (1) WO2017121850A1 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6854823B2 (ja) 2016-01-13 2021-04-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 3−(カルボキシメチル)−8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体
PL3402781T3 (pl) 2016-01-13 2020-09-21 Grünenthal GmbH Pochodne 3-((hetero-)arylo)-8-amino-2-okso-1,3-diazaspiro-[4.5]-dekanu
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
EA034898B1 (ru) 2016-01-13 2020-04-03 Грюненталь Гмбх Производные 8-амино-2-оксо-1,3-диазаспиро[4,5]декана
LT3402784T (lt) 2016-01-13 2020-06-10 Grünenthal GmbH 3-((hetero-)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
EP3655426A1 (en) * 2017-07-19 2020-05-27 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof
EP3655427A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Bifunctional compounds
WO2019023295A1 (en) * 2017-07-27 2019-01-31 Saint Louis University Fatty acid modified human epidermal growth factor
JOP20190150A1 (ar) 2018-06-21 2019-12-21 Merck Sharp & Dohme مركبات مناهضة لـ pcsk9
TW202028229A (zh) 2018-10-05 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 包含胰島素肽及egf(a)肽之雙功能化合物
MX2021010767A (es) 2019-03-22 2021-09-28 3M Innovative Properties Company Sistema de proteccion contra caidas con sistema de monitoreo.
CN110357969B (zh) * 2019-05-27 2022-03-08 北京志道生物科技有限公司 一种GLP1-EGFa异源二聚体蛋白、功能及方法
BR112022000529A2 (pt) 2019-08-07 2022-03-03 Novo Nordisk As Composição farmacêutica
IL291893A (en) 2019-11-07 2022-06-01 Novo Nordisk As Solid compositions comprising a pcsk9 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
JP2024527488A (ja) 2021-07-02 2024-07-25 スリーエム イノベイティブ プロパティズ カンパニー 落下防止安全装置と連動される空中リフト
WO2023012263A1 (en) 2021-08-04 2023-02-09 Novo Nordisk A/S Solid oral peptide formulations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP1909823A2 (en) 2005-07-29 2008-04-16 Amprotein Corporation Chimeric therapeutic agents
ES2526924T3 (es) 2007-08-15 2015-01-16 Novo Nordisk A/S Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol
WO2009131740A2 (en) 2008-04-23 2009-10-29 Amgen Inc. Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Pcsk9拮抗劑類
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
JPWO2012017774A1 (ja) * 2010-08-02 2013-10-03 日本電気株式会社 偏光子及び発光装置
CN102153652A (zh) 2010-12-10 2011-08-17 浙江大学 一种融合蛋白的表达方法及用途
CN103370075A (zh) 2011-02-15 2013-10-23 诺沃—诺迪斯克有限公司 长效il-1受体拮抗剂
EP2721063A4 (en) 2011-06-20 2015-01-14 Hoffmann La Roche PCSK9 BINDING POLYPEPTIDES AND METHOD OF USE THEREOF
EP2758426B1 (en) * 2011-09-23 2019-08-07 Novo Nordisk A/S Novel glucagon analogues
TW201315742A (zh) 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
JP2015502971A (ja) * 2011-12-21 2015-01-29 ノヴォ ノルディスク アー/エス N末端修飾インスリン誘導体
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
AR092076A1 (es) 2012-08-22 2015-03-18 Lilly Co Eli Proteinas homodimericas
CN104736558A (zh) 2012-09-07 2015-06-24 赛诺菲 用于治疗代谢综合征的融合蛋白
MX362275B (es) * 2013-04-18 2019-01-10 Novo Nordisk As Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
BR112016017402A2 (pt) 2014-02-21 2017-10-17 Medimmune Ltd fusões anti-pcsk9~glp-1 e métodos para uso
EP3151852A1 (en) * 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
CN104558198A (zh) 2014-07-25 2015-04-29 成都贝爱特生物科技有限公司 GLP-1类似物和amylin类似物的融合蛋白制备及其用途
CA2979617C (en) * 2015-03-19 2024-01-02 Institut De Cardiologie De Montreal Grp94 derived polypeptides for inhibiting pcsk9 and methods of use
CN105367884A (zh) 2015-11-02 2016-03-02 陈薇 一种绝缘耐火抗辐射的屏蔽电缆材料及其制备方法
MY195199A (en) 2016-01-13 2023-01-11 Novo Nordisk As EGF(A) Analogues with Fatty Acid Substituents
EP3655426A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof
EP3655427A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Bifunctional compounds

Also Published As

Publication number Publication date
RS63298B1 (sr) 2022-07-29
EP3402811A1 (en) 2018-11-21
US20200407409A1 (en) 2020-12-31
US20190016768A1 (en) 2019-01-17
WO2017121850A1 (en) 2017-07-20
MX2018008681A (es) 2018-09-17
SI3402811T1 (sl) 2022-06-30
ES2916998T3 (es) 2022-07-06
PE20181376A1 (es) 2018-09-05
AU2017207862A1 (en) 2018-07-05
HUE058647T2 (hu) 2022-09-28
CL2018001868A1 (es) 2018-08-31
LT3402811T (lt) 2022-06-10
CN108473550A (zh) 2018-08-31
JP2019505521A (ja) 2019-02-28
EP3402811B1 (en) 2022-03-30
CO2018007440A2 (es) 2018-09-28
HRP20220720T1 (hr) 2022-09-30
PH12018501502A1 (en) 2019-03-25
US10822385B2 (en) 2020-11-03
RU2747877C2 (ru) 2021-05-17
CA3010756A1 (en) 2017-07-20
PL3402811T3 (pl) 2022-07-11
RU2018127882A (ru) 2020-02-13
CN108473550B (zh) 2022-11-22
IL260043A (en) 2018-07-31
DK3402811T3 (da) 2022-06-13
KR20180100177A (ko) 2018-09-07
KR102417487B1 (ko) 2022-07-06
JP6797926B2 (ja) 2020-12-09
JP2021035989A (ja) 2021-03-04
SA518391996B1 (ar) 2021-07-14
MY195199A (en) 2023-01-11
AU2017207862B2 (en) 2020-12-17
BR112018013820A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
BR112019009389A2 (ru)
BR122021013712A2 (ru)
RU2018127882A3 (ru)
BR122020022459A2 (ru)
BR112019009192A2 (ru)
BR112019006736A2 (ru)
BR202016025584U2 (ru)
BR202016021516U2 (ru)
CN303585247S (ru)
CN303664072S (ru)
CN303631348S (ru)
CN303536246S (ru)
CN303628373S (ru)
CN303628021S (ru)
CN303536232S (ru)
CN303536208S (ru)
CN303536129S (ru)
CN303611828S (ru)
CN303535547S (ru)
CN303609244S (ru)
CN303606578S (ru)
CN303604680S (ru)
CN303591892S (ru)
CN303539132S (ru)
CN303660154S (ru)